- Novavax ( NASDAQ: NVAX ) announced Friday that the Israel Ministry of Health greenlighted the use of its COVID-19 vaccine Nuvaxovid in those aged 12 years and above for immunization against coronavirus disease.
- The import and use permit issued by the ministry allows the use of the vaccine as a primary series and as a heterologous booster in those who have previously received messenger RNA vaccines.
- The decision was based on a recommendation by the Israeli Advisory Committee on Epidemics.
- "Nuvaxovid is now available for use in Israel in individuals aged 12 and older as both a primary series and a booster regardless of previous vaccine history," Chief Executive Stanley C. Erck remarked.
- Israel, one of the first few countries to rollout COVID-19 vaccines, has struck an agreement to procure 5M doses of Novavax ( NVAX ) COVID-19 vaccine, Reuters reported in January.
For further details see:
Novavax COVID-19 shot available in Israel for those aged 12 and above